#United States #New York #Class Action #Securities Fraud #MoonLake Immunotherapeutics

Important Notice for MoonLake Investors

Levi & Korsinsky, LLP has alerted investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) about a significant class action lawsuit. This action primarily focuses on alleged securities fraud impacting the stock prices between March 10, 2024, and September 29, 2025. The firm is reaching out to affected investors to ensure they are informed about their rights and potential recovery processes.

Overview of the Lawsuit

The lawsuit aims to recover losses sustained by MoonLake investors who claim to have been harmed by misleading information disseminated by the company. Central to the claims are assertions regarding MoonLake’s key drug candidates, SLK and BIMZELX, and their claimed benefits. The allegations suggest that the company misrepresented the efficacy and clinical advantages of its drug candidate, SLK, which reportedly shares the same molecular targets as BIMZELX but has been falsely touted as having superior benefits.

The complaint details several significant points:
1. Misleading Statements: It is alleged that the defendants, which include key executives, made false statements and concealed critical information about the clinical characteristics and benefits of SLK.
2. False Superiority Claims: The lawsuit claims that the unique structure of SLK was erroneously marketed as significantly superior to the traditional monoclonal antibody structure of BIMZELX.
3. Efficacy Misrepresentation: It alleges that any supposed advantages in terms of tissue penetration and associated clinical outcomes of SLK were overstated or unfounded.
4. Unreasonable Optimism: The basis for positive claims about SLK’s superiority against monoclonal antibodies was allegedly flawed, leading to substantial financial losses for investors once these truths came to light.

Next Steps for Investors

For investors who have suffered significant financial losses during the specified period, the timeline to act is critical. They have until December 15, 2025, to request that the Court appoint them as lead plaintiff in the class action. However, it is essential to clarify that participating in any recovery process does not necessitate leading the suit. Investors can still recover damages without taking on that role.

No Out-of-Pocket Costs

Levi & Korsinsky emphasizes that there is no financial obligation to join the class action. Investors do not have to pay any attorney fees, ensuring that they can pursue their claims without the burden of upfront costs. The law firm affirms its commitment to providing access to justice and ensuring that investors can reclaim losses due to corporate malpractice.

Levi & Korsinsky’s Reputation

Having a robust track record of over two decades in investor representation, Levi & Korsinsky has recovered hundreds of millions for aggrieved shareholders. Their history of handling high-stakes securities litigation underlines the firm’s capability and commitment to defending investor rights. The firm's expertise has earned it recognition as one of the top securities litigation firms in the United States for several consecutive years.

Contact Information

For those wishing to learn more about their involvement in this class action lawsuit or to discuss the implications further, interested parties can reach out to Joseph E. Levi, Esq., via email at [email protected] or by phone at (212) 363-7500. More information can also be found on their website.

This class action serves as a crucial reminder of investment vigilance and the need to stay informed about corporate communications regarding potential impacts on investor portfolios.